CHAPEL HILL, N.C., March 31 The landscape of scientificpublications strategy, planning and delivery is changing with the advent oftransparency guidelines. Half of global publications groups are fully locatedin the marketing function, but publications leaders foresee a shift to medicalgroups to increase clinical presentation, according to a new report releasedby Best Practices, LLC.
In a benchmarking study that included such influential companies asPfizer, GlaxoSmithKline, Lilly and Merck, it was found that 14 percent ofparticipating pharmaceutical and biotech companies avoid using global orregional marketing representatives to develop their global publicationsstrategy. These companies, which align publications strictly within themedical group, receive strategic input from medical directors, advisorphysicians and biostatisticians.
For a complimentary summary of the full report "Scientific PublicationsStrategy: Managing Reputation, Clinical Trial Results and CommercialRelevance," click on the following linkhttp://www3.best-in-class.com/rr790.htm . The study guides pharmaceutical andbiotechnology companies in the transition to the new publishing environment tocreate the desired synergy between credibility of scientific rigor andincreased commercial success.
For more information on this report, contact Robert Naylor firstname.lastname@example.org or (919) 767-9244. To access the full report ordownload a complimentary copy of the report summary, go tohttp://www3.best-in-class.com/rr790.htm .
ABOUT BEST PRACTICES, LLC
Best Practices, LLC, conducts work based on the simple yet profoundprinciple that organizations can chart a course to superior economicperformance by studying the best business practices, operating tactics andwinning strategies of world-class companies. For more than 15 years, ourhighly credentialed research staff has conducted primary research exclusivelyfor our Fortune 500 client base.Other key topic areas in the research include: -- Impact of transparency guidelines on publications, planning and delivery -- Tactics for handling publication of neutral or negative clinical trial results -- Optimal structure for the global publications function -- Transition of global publication function from commercial to clinical -- Strategy changes for the new marketplace Among the key topics gathered in this report are: -- Centralization of publications strategy, planning and delivery -- Trends surrounding regional strategy contribution -- Strategies for publishing neutral/negative results -- Outsourcing of global publications resources -- Measures used for performance evaluation
SOURCE Best Practices, LLC